Is your therapist AI? ChatGPT goes viral on social media for its role as Gen Z's new therapist
AI chatbots are stepping into the therapist's chair – and not everyone is thrilled about it.
In March alone, 16.7 million posts from TikTok users discussed using ChatGPT as a therapist, but mental health professionals are raising red flags over the growing trend that sees artificial intelligence tools being used in their place to treat anxiety, depression and other mental health challenges.
"ChatGPT singlehandedly has made me a less anxious person when it comes to dating, when it comes to health, when it comes to career," user @christinazozulya shared in a TikTok video posted to her profile last month.
"Any time I have anxiety, instead of bombarding my parents with texts like I used to or texting a friend or crashing out essentially… before doing that, I always voice memo my thoughts into ChatGPT, and it does a really good job at calming me down and providing me with that immediate relief that unfortunately isn't as accessible to everyone."
Parents Trust Ai For Medical Advice More Than Doctors, Researchers Find
Others are using the platform as a "crutch" as well, including user @karly.bailey, who said she uses the platform "all the time" for "free therapy" as someone who works for a startup company and doesn't have health insurance.
Read On The Fox News App
"I will just tell it what's going on and how I'm feeling and literally all the details as if I were yapping to a girlfriend, and it'll give me the best advice," she shared.
"It also gives you journaling prompts or EFT (emotional freedom tapping)… it'll give you whatever you want."
These users are far from alone. A study from Tebra, an operating system for independent healthcare providers, found that "1 in 4 Americans are more likely to talk to an AI chatbot instead of attending therapy."
In the U.K., some young adults are opting for the perceived benefits of a handy AI mental health consultant over long National Health Service (NHS) wait times and to avoid paying for private counseling, which can cost around £400 (approximately $540).
According to The Times, data from Rethink Mental Illness found that over 16,500 people in the U.K. were still waiting for mental health services after 18 months, indicating that cost burdens, wait times and other hurdles that come with seeking healthcare can exacerbate the urge to use a more cost-effective, convenient method.
I'm A Tech Expert: 10 Ai Prompts You'll Use All The Time
But, while critics say these virtual bots may be accessible and convenient, they also lack human empathy, and could put some who are in crisis mode at risk of never receiving the tailored approach they need.
"I've actually spoken to ChatGPT, and I've tested out a couple of prompts to see how responsive they are, and ChatGPT tends to get the information from Google, synthesize it, and [it] could take on the role of a therapist," Dr. Kojo Sarfo, a social media personality and mental health expert, told Fox News Digital.
Some GPTs, such as the Therapist GPT, are specifically tailored to provide "comfort, advice and therapeutic support."
While perhaps more cost-effective than traditional therapy at $20 per month for ChatGPT Plus, which allows user benefits like unlimited access, faster response times and more, the platform fails to extend as far as professionals who can make diagnoses, prescribe medications, monitor progress or mitigate severe problems.
"It can feel therapeutic and give support to people, but I don't think it's a substitute for an actual therapist who is able to help you navigate through more complex mental health issues," Sarfo added.
Woman Says Chatgpt Saved Her Life By Helping Detect Cancer, Which Doctors Missed
He said the danger lies in those who conflate the advice from a tool like ChatGPT with legitimate advice from a licensed professional who has years of expertise in handling mental health issues and has learned how to tailor their approach to diverse situations.
"I worry specifically about people who may need psychotropic medications, that they use artificial intelligence to help them feel better, and they use it as a therapy. But sometimes... Therapy and medications are indicated. So there's no way to get the right treatment medication-wise without going to an actual professional. So that's one thing that can't be outsourced to artificial intelligence."
However, some aspects of the chatbot could be beneficial to those needing support, particularly those who are looking for ways to chat with their doctor about conditions they believe they may have – such as ADHD – to empower them with knowledge they can carry to their appointment.
"[You can] list out a couple of prompts that are assertive, and you can state those prompts to your provider and articulate your symptoms a bit better, so I think that's a helpful role that artificial intelligence can play, but in terms of actual therapy or actual medical advice, if people start to rely on it, it's a bad thing. It starts to go into murky waters," Sarfo said.
Earlier this year, Christine Yu Moutier, M.D., Chief Medical Officer at the American Foundation for Suicide Prevention, warned against using the technology for mental health advice, telling Fox News Digital there are "critical gaps" in research regarding the intended and unintended impacts of AI on suicide risk, mental health and larger human behavior.
"The problem with these AI chatbots is that they were not designed with expertise on suicide risk and prevention baked into the algorithms. Additionally, there is no helpline available on the platform for users who may be at risk of a mental health condition or suicide, no training on how to use the tool if you are at risk, nor industry standards to regulate these technologies," she said.
Dr. Moutier also explained that, since chatbots may fail to decipher metaphorical from literal language, they may be unable to adequately determine whether someone is at risk of self-harm.
Fox News' Nikolas Lanum contributed to this report.Original article source: Is your therapist AI? ChatGPT goes viral on social media for its role as Gen Z's new therapist
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
A Health Crisis Cost You a Bundle. How to Claw It Back.
Americans undergoing a major medical event or relying on assisted care at home or in a facility should put the deduction on their radar, tax experts say. 'Make sure you've got proof of payment for any out-of-pocket cost, everything to support that deduction,' said Henry Grzes, lead manager for tax practice and ethics with the American Institute of CPAs. What Is the Medical Tax Deduction?
Yahoo
3 hours ago
- Yahoo
Palantir and TeleTracking Team Up to Enhance Healthcare Operations Using AI-Driven Insights
TeleTracking Technologies, a leading provider of healthcare operations platforms, has teamed up with Palantir Technologies Inc. (NASDAQ:PLTR), known for its expertise in artificial intelligence systems. The two companies have formed a strategic partnership with the goal of transforming how hospitals and health systems make operational decisions, ultimately creating long-term value for healthcare providers around the world. The collaboration will integrate TeleTracking's Operations IQ platform with Palantir Technologies Inc. (NASDAQ:PLTR)'s AI-driven tools, including Foundry and AIP. This combined solution is expected to equip hospitals with near real-time, actionable insights to improve staffing efficiency, speed up decision-making, and ensure that patient needs remain the top priority. As healthcare systems continue to face increasing demands to enhance capacity and coordination without expanding their physical footprint, this partnership represents a significant step forward. By bringing together TeleTracking's operational strengths and Palantir Technologies Inc. (NASDAQ:PLTR)'s cutting-edge technology, the two aim to usher in a new era of intelligent, scalable, and efficient healthcare delivery. Alex Karp, CEO at Palantir Technologies Inc. (NASDAQ:PLTR) made the following comment: 'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of—where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care.' Palantir Technologies Inc. (NASDAQ:PLTR) is an American publicly traded company that focuses on developing software platforms designed for analyzing large volumes of data. While we acknowledge the potential of PLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus